Co-Authors
This is a "connection" page, showing publications co-authored by Timothée Klopfenstein and Vincent Gendrin.
Connection Strength
3.782
-
Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France. Microorganisms. 2021 Aug 12; 9(8).
Score: 0.240
-
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia. Infect Dis Ther. 2021 Sep; 10(3):1195-1213.
Score: 0.239
-
Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'. Ann Rheum Dis. 2021 Jun 23.
Score: 0.238
-
Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022 01; 32(1):e2239.
Score: 0.235
-
Recurrence of COVID-19 after recovery ? A case series in health care workers, France. Microbes Infect. 2021 May-Jun; 23(4-5):104803.
Score: 0.233
-
Is There Still a Place for Tocilizumab in Coronavirus Disease 2019? Open Forum Infect Dis. 2021 Feb; 8(2):ofab013.
Score: 0.231
-
Angioedema and COVID-19: A New Dermatological Manifestation? Infect Dis Rep. 2021 Jan 01; 13(1):23-25.
Score: 0.230
-
Comparison of COVID-19 and influenza in adult patients: Neurological symptoms input. J Med Virol. 2021 04; 93(4):1893-1895.
Score: 0.230
-
Natural history of COVID-19: back to basics. New Microbes New Infect. 2020 Nov; 38:100815.
Score: 0.228
-
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct; 99:491-495.
Score: 0.224
-
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. Int J Infect Dis. 2020 Nov; 100:117-122.
Score: 0.224
-
Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect. 2020 10; 22(9):481-488.
Score: 0.222
-
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020 Aug; 50(5):397-400.
Score: 0.220
-
Diarrhea: An underestimated symptom in Coronavirus disease 2019. Clin Res Hepatol Gastroenterol. 2020 06; 44(3):282-283.
Score: 0.220
-
Features of anosmia in COVID-19. Med Mal Infect. 2020 Aug; 50(5):436-439.
Score: 0.219
-
It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2022 02 11; 74(3):560-562.
Score: 0.062
-
Distinguishing coronavirus disease 2019 from influenza in children remains challenging. New Microbes New Infect. 2021 May; 41:100888.
Score: 0.059
-
A Comparative Systematic Review of COVID-19 and Influenza. Viruses. 2021 03 10; 13(3).
Score: 0.058
-
Coronavirus disease 2019 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema, France. New Microbes New Infect. 2020 Nov; 38:100785.
Score: 0.057
-
Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):742-747.
Score: 0.056
-
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Microbes Infect. 2020 10; 22(9):500-503.
Score: 0.056